Form 4: BioAtla Director Eddie Williams Granted Restricted Stock Units

BioAtla, Inc. Director Eddie Williams was granted 23,500 shares of common stock in the form of restricted stock units, increasing his beneficial ownership to 60,200 shares.

Summary

• The reporting person is Eddie Williams, a Director of BioAtla, Inc. (BCAB).
• On June 18, 2025, Mr. Williams acquired 23,500 shares of BioAtla Common Stock.
• This acquisition was in the form of a time-based restricted stock unit (RSU) award, with an acquisition price of $0 per share.
• Following this transaction, Eddie Williams' beneficial ownership of BioAtla Common Stock increased to 60,200 shares.
• The RSU award will vest 100% on the earlier of June 18, 2026, or the next Company annual meeting of stockholders, subject to Mr. Williams' continued service through the vesting date.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is a positive event as it aligns the director's interests with the long-term performance of the company and its shareholders.

Positives

• The grant of restricted stock units to a director aligns their long-term interests with those of the company's shareholders.
• Increases the director's beneficial ownership in the company, demonstrating continued commitment.

Risks

• The vesting of the restricted stock units is contingent upon the reporting person's continued service to the company through the specified vesting date.

Future Outlook

The RSU award's future vesting schedule indicates an expectation of continued service from the director, aligning their long-term incentives with the company's performance.

Industry Context

This transaction represents a standard form of equity compensation for directors in publicly traded companies, particularly within the biotechnology sector, designed to align the interests of the board with long-term shareholder value creation.

Comparison to Industry Standards

• Granting restricted stock units (RSUs) to directors is a common practice across publicly traded companies, including those in the biotechnology sector, as a form of non-cash compensation.
• The vesting schedule, tied to continued service and a specific future date or annual meeting, is typical for such awards, similar to practices at companies like Amgen (AMGN) or Gilead Sciences (GILD) for their non-employee directors.
• The $0 price reflects that this is an equity grant, not a stock purchase, which is standard for RSU awards.

Stakeholder Impact

• Shareholders: Positive, as the director's interests are further aligned with shareholder value through increased equity ownership.

Next Steps

• Continued service of Eddie Williams through the vesting date.
• Vesting of 23,500 shares on the earlier of June 18, 2026, or the next Company annual meeting of stockholders.

Key Dates

Recommendation

Keywords

BioAtla, BCAB, Eddie Williams, Form 4, SEC filing, restricted stock units, RSU, insider transaction, director compensation, equity grant